These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 1824981

  • 1. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R, Bluestone JA, Bare CV, Gress RE.
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract] [Full Text] [Related]

  • 2. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
    Hirsch R, Bluestone JA, DeNenno L, Gress RE.
    Transplantation; 1990 Jun 01; 49(6):1117-23. PubMed ID: 2141740
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE.
    J Immunol; 1986 Jun 01; 136(11):3945-52. PubMed ID: 3084650
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B, Schwinzer R, Wonigeit K, Pichlmayr R.
    Transplant Proc; 1989 Feb 01; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract] [Full Text] [Related]

  • 15. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
    Vaessen LM, Kreeftenberg JG, Heyse P, Leerling MF, Baumgartner D, Hendriks GF, Jutte NH, Weimer W.
    Transplant Proc; 1989 Feb 01; 21(1 Pt 1):1026-7. PubMed ID: 2523112
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.
    Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R.
    Diabetes; 1992 Mar 01; 41(3):385-91. PubMed ID: 1532369
    [Abstract] [Full Text] [Related]

  • 19. Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection.
    Campos HH, Bach JF, Chatenoud L.
    Transplant Proc; 1993 Feb 01; 25(1 Pt 1):798-9. PubMed ID: 8438486
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.